September 1, 2024 Issue of JAMA Oncology

September 2024, Vol 10, No. 9, Pages 1161-1296

Original Investigation

Recurrence of Non鈥揝mall Cell Lung Cancer With Visceral Pleural Invasion: A Secondary Analysis of a Randomized Clinical Trial

Nasser Altorki, MD; Xiaofei Wang, PhD; Bryce Damman, MS; et al.

Abstract Full Text

JAMA Oncol. 2024;10(9):1179-1186. doi:10.1001/jamaoncol.2024.2491

This secondary analysis of the Cancer and Leukemia Group B 140503 randomized clinical trial examines survival and recurrence rates in patients with small peripheral pT2 non鈥搒mall cell lung cancer that was treated by either lobar or sublobar resection.

Editorial
Sublobar Resection vs Lobectomy for High-Risk Stage I Non鈥揝mall Cell Lung Carcinoma
Jay M. Lee, MD

JAMA Oncol

Neoadjuvant Exercise Therapy in Prostate Cancer: A Phase 1, Decentralized Nonrandomized ControlledTrial

Lee W. Jones, PhD; Chaya S. Moskowitz, PhD; Catherine P. Lee, BS, MPH; et al.

Abstract Full Text

has audio

JAMA Oncol. 2024;10(9):1187-1194. doi:10.1001/jamaoncol.2024.2156

This nonrandomized clinical trial examines 6 escalated exercise therapy dose levels ranging from 90 to 450 minutes per week for men with treatment-naive localized prostate cancer.

Podcast: Neoadjuvant Exercise Therapy in Prostate Cancer

Editorial
Exercise for Prostate Cancer鈥擶orthy Goals but Suboptimal Trial Designs
Marian L. Neuhouser, PhD, RD; Jeannette M. Schenk, PhD, RD; Jonathan L. Wright, MD, MS

JAMA Oncol

Response-Adapted Ultralow-Dose Radiation Therapy for Orbital Indolent B-Cell Lymphoma: A Phase 2 Nonrandomized Controlled Trial

Chelsea C. Pinnix, MD, PhD; Bouthaina S. Dabaja, MD; Jillian R. Gunther, MD, PhD; et al.

Abstract Full Text

JAMA Oncol. 2024;10(9):1195-1203. doi:10.1001/jamaoncol.2024.2112

This nonrandomized controlled trial aims to determine if a response-adapted radiation therapy strategy will result in excellent disease outcomes while reducing orbital morbidity.

Bintrafusp Alfa for Recurrent or Metastatic Cervical Cancer After Platinum Failure: A Nonrandomized Controlled Trial

Michael Birrer, MD, PhD; Guiling Li, MD; Mayu Yunokawa, MD, PhD; et al.

Abstract Full Text

open access

JAMA Oncol. 2024;10(9):1204-1211. doi:10.1001/jamaoncol.2024.2145

This phase 2 nonrandomized controlled trial evaluates the safety and response rates of bintrafusp alfa in patients with recurrent or metastatic cervical cancer.

Atezolizumab Before and After Chemoradiation for Unresectable Stage III Non鈥揝mall Cell Lung Cancer: A Phase II Nonrandomized Controlled Trial

Helen J. Ross, MD; David Kozono, MD, PhD; Xiaofei F. Wang, PhD; et al.

Abstract Full Text

JAMA Oncol. 2024;10(9):1212-1219. doi:10.1001/jamaoncol.2024.1897

This nonrandomized controlled trial evaluates the clinical outcomes of atezolizumab treatment before and after chemoradiation therapy for unresectable stage III non鈥搒mall cell lung cancer (NSCLC).

Editor's Note
Immunotherapy Before Chemoradiotherapy鈥擬ore Is Better?
Narjust Florez, MD

JAMA Oncol

Measurable Residual Disease and Clinical Outcomes in Chronic Lymphocytic Leukemia: A Systematic Review and Meta-Analysis

Fausto Alfredo Rios-Olais, MD; Alyssa K. McGary, MS; Mazie Tsang, MD, MS; et al.

Abstract Full Text

JAMA Oncol. 2024;10(9):1221-1227. doi:10.1001/jamaoncol.2024.2122

This systematic review and meta-analysis assesses the association between measurable residual disease and progression-free survival in chronic lymphocytic leukemia treated with targeted agents.

Bilateral Mastectomy and Breast Cancer Mortality

Vasily Giannakeas, PhD, MPH; David W. Lim, MDCM, MEd, PhD; Steven A. Narod, MD

Abstract Full Text

JAMA Oncol. 2024;10(9):1228-1236. doi:10.1001/jamaoncol.2024.2212

This cohort study estimates the 20-year cumulative risk of breast cancer mortality among women with stage 0 to III unilateral breast cancer according to the type of initial surgery performed.

Editorial
Contralateral Breast Cancer Remains a Complex Biologic Conundrum
Seema Ahsan Khan, MD; Masha Kocherginsky, PhD

JAMA Oncol

Waterpipe Tobacco Smoking and Risk of Cancer Mortality

Ngoan Tran Le, MD, PhD; Can Van Phan, MSc; Yen Thi-Hai Pham, MD, MSc; et al.

Abstract Full Text

JAMA Oncol. 2024;10(9):1237-1244. doi:10.1001/jamaoncol.2024.1939

This cohort study evaluates the association between waterpipe tobacco smoking and the risk of cancer mortality in Vietnam.

Assessing the Environmental and Downstream Human Health Impacts of Decentralizing Cancer Care

Andrew Hantel, MD; Colin Cernik, MS; Thomas P. Walsh, MPH; et al.

Abstract Full Text

JAMA Oncol. 2024;10(9):1245-1252. doi:10.1001/jamaoncol.2024.2744

This cohort study assesses potential reductions in greenhouse gas emissions and downstream health harms associated with telemedicine and fully decentralized cancer care.

Brief Report

Immunotherapy vs Best Supportive Care for Patients With Hepatocellular Cancer With Child-Pugh B Dysfunction

Claudia Angela Maria Fulgenzi, MD; Bernhard Scheiner, PhD; Antonio D鈥橝lessio, MD; et al.

Abstract Full Text

JAMA Oncol. 2024;10(9):1253-1258. doi:10.1001/jamaoncol.2024.2166

This case series examines the association of immune checkpoint inhibitor鈥揵ased therapies vs best supportive care with the overall survival of patients with unresectable hepatocellular carcinoma and Child-Pugh class B liver dysfunction.

B-Cell Maturation Antigen/CD19 Dual-Targeting Immunotherapy in Newly Diagnosed Multiple Myeloma

Wanting Qiang, MSc; Jing Lu, MD; Yanchun Jia, MSc; et al.

Abstract Full Text

open access

JAMA Oncol. 2024;10(9):1259-1263. doi:10.1001/jamaoncol.2024.2172

This single-arm, open-label phase 1 cohort study examines the safety, patient health, and survival outcomes of GC012F in individuals with high-risk newly diagnosed multiple myeloma.

Research Letter

Characterizing Lung Cancer in Li-Fraumeni Syndrome

Jessica N. Hatton, MS; John Kucera, MD; Kenneth P. Seastedt, MD; et al.

Abstract Full Text

JAMA Oncol. 2024;10(9):1284-1287. doi:10.1001/jamaoncol.2024.2511

This cohort study describes lung cancer incidence, diagnosis, and outcome in individuals with Li-Fraumeni syndrome.

Population-Based Incidence of Cervical Intraepithelial Neoplasia Across 14 Years of HPV Vaccination

Rachael Adcock, PhD; Huining Kang, PhD; Philip E. Castle, PhD, MPH; et al.

Abstract Full Text

JAMA Oncol. 2024;10(9):1287-1290. doi:10.1001/jamaoncol.2024.2673

This cohort study examines the incidence of cervical intraepithelial neoplasia during a period of increasing human papillomavirus (HPV) vaccination coverage from 2007 to 2020.

Special Communication

Initial Management of BRAF V600E-Variant Anaplastic Thyroid Cancer: The FAST Multidisciplinary Group Consensus Statement

Sarah Hamidi, MD; Ramona Dadu, MD; Mark E. Zafereo, MD; et al.

Abstract Full Text

has active quiz

JAMA Oncol. 2024;10(9):1264-1271. doi:10.1001/jamaoncol.2024.2133

This Consensus Statement summarizes new evidence-based recommendations and reaffirms standards for timely initial management of BRAF V600E-variant anaplastic thyroid cancer.

Review

BRCA1, BRCA2, and Associated Cancer Risks and Management for Male Patients: A Review

Heather H. Cheng, MD, PhD; Jeffrey W. Shevach, MD; Elena Castro, MD, PhD; et al.

Abstract Full Text

has active quiz

JAMA Oncol. 2024;10(9):1272-1281. doi:10.1001/jamaoncol.2024.2185

This narrative review describes the identification of male BRCA1/2 pathogenic variant carriers, associated cancer risks, and management recommendations.

JAMA Oncology Clinical Challenge

A Case of Gastric Thickening and a Large Ovarian Mass

Binbin Zheng-Lin, MD, MSc; Katalin Kelemen, MD, PhD; Allison Rosenthal, DO

Abstract Full Text

has active quiz

JAMA Oncol. 2024;10(9):1282-1283. doi:10.1001/jamaoncol.2024.1816

A 35-year-old female patient with hypothyroidism and Ehler-Danlos syndrome presents with fatigue, abdominal distension, and dyspnea. What is your diagnosis?

Viewpoint

Sexual Rehabilitation Needs of Gay and Bisexual Men With Cancer

Christopher W. Wheldon, PhD

Abstract Full Text

JAMA Oncol. 2024;10(9):1167-1168. doi:10.1001/jamaoncol.2024.1586

This Viewpoint discusses the importance of concentrating research efforts and clinical training on sexual and gender minority individuals who survive cancer, particularly on sexual rehabilitation.

Postoperative Management of Prostate Cancer鈥擮ptimizing Prostate Cancer Care

Mutlay Sayan, MD; Derya Tilki, MD; Anthony V. D鈥橝mico, MD, PhD

Abstract Full Text

JAMA Oncol. 2024;10(9):1169-1170. doi:10.1001/jamaoncol.2024.1887

This Viewpoint discusses the end point analyses and results of the RACICALS-RT study.

Advancing Genomic Cancer Medicine in Rural and Underserved States

Jens Rueter, MD; Edison T. Liu, MD

Abstract Full Text

JAMA Oncol. 2024;10(9):1171-1172. doi:10.1001/jamaoncol.2024.1926

This Viewpoint presents an organizational and social template for medical communities to provide contemporary care for patients with cancer in rural and underserved states.

Editorial